Pressmeddelanden – endast tillgängliga på engelska

  • May 28th, 2015
    Cerbomed expands availability: transcutaneous Vagus Nerve Stimulation for epilepsies now available in Norway. [read]

  • May 28th, 2015
    Cerbomed with further partnership: Vagus nerve stimulation without surgery now available in Denmark, Finland and Sweden. [read]

  • April 30th, 2015
    Trial results for transcutaneous Vagus Nerve Stimulation in pharmacoresistant epilepsy: Cerbomed GmbH at the 9th Dreiländertagung in Dresden [read]
  • February 3rd, 2015
    transcutaneous Vagus Nerve Stimulation with NEMOS now also available for epilepsy patients in the UK [read]
  • June 30th, 2014
    Cerbomed GmbH at the 11th European Congress on Epileptology in Stockholm [read]

  • March 13th, 2014
    Cerbomed GmbH at the 30th International Congress of Clinical Neurophysiology [read]
  • September 12th, 2013
    Cerbomed GmbH at the 86th Congress of the German Society of Neurology [read]

  • June 6th, 2013
    Cerbomed at the INS 11th World Congress in Berlin [read]

  • February 21st, 2013
    Cerbomed opens up new markets: From March on t-VNS with NEMOS will be available in Italy for the treatment of epilepsies [read]

  • November 20th, 2012
    Cerbomed GmbH presents transcutaneous Vagus Nerve Stimulation at the 8th annual meeting of the German Society of Neuromodulation [read]

  • September 24th, 2012
    Cerbomed GmbH at the 35th Congress of the German Society of Neurology [read]

  • September 21st, 2012
    Cerbomed announces Cyberonics as new investor and shareholder [read]

  • August 23rd, 2012
    Cerbomed GmbH: transcutaneous Vagus Nerve Stimulation for pain relief [read]

  • June 21st, 2012
    Cerbomed GmbH: Start of a multi-center trial into t-VNS for drug-resistant epilepsy [read]

  • May 22nd, 2012
    Cerbomed GmbH: First patient included in the chronic migraine trial. [read]

  • March 8th, 2012
    A renewed web presence for cerbomed GmbH [read]

  • March 8th, 2012
    Cerbomed GmbH at the 10th annual meeting of the Austrian Society for Neurology (ÖGN) [read]

  • February 23rd, 2012
    Cerbomed at the 51st annual conference of the German Society for Epileptology [read]

  • February 21st, 2012
    Expertise in epilepsy treatment: Prof. Dr. med. Hajo Hamer reinforces the scientific advisory board of cerbomed GmbH [read]

  • November 22nd, 2011
    Cerbomed at the 7th annual meeting of the German Society of Neuromodulation [read]
  • June 22nd, 2011
    Cerbomed at the 4th International Epilepsy Colloquium in Marburg [read]
  • June 16th, 2011
    Promising results for a study into using transcutaneous Vagus nerve stimulation for hard to treat epilepsies [read]
  • May 17th, 2011
    Cerbomed at the INS 10th World Congress [read]
  • May 12th, 2011
    Expanding competences: cerbomed GmbH gains Prof. Dr. Barry R. Komisaruk for its scientific advisory board. [read]
  • February 14th, 2011
    Cerbomed appoints new Chairman and expands Advisory Board [read]
  • January 27th, 2011
    Prof. Dr. Christian E. Elger joins the scientific advisory board at cerbomed GmbH [read]
  • January 24th, 2011
    A new study proves the painkilling effect of transcutaneous Vagus Nerve Stimulation at man [read]
  • August 4th, 2010
    cerbomed announces Prof. Dr. med Jens Ellrich as Chief Medical Officer (CMO) [read]
  • June 7th, 2010
    cerbomed reports positive intermediate results from epilepsy pilot study [read]
  • June 1st, 2010
    New management team at cerbomed [read]
  • March 19th, 2010
    cerbomed gets CE labeling for transcutaneous vagus nerve stimulator [read]

  • August 9th, 2009
    cerbomed reaches another milestone with its ISO 13485-certification [read]

  • July 10th, 2009
    cerbomed announces the inclusion of the first patient in a clinical trial for the therapy of difficult-to-treat epilepsies using transcutaneous vagus nerve stimulation (t-VNS®) [read]

  • May 28th, 2009
    Dr. Andreas Hartlep is the new Chief Technology Officer at cerbomed [read]


Har du frågor om NEMOS® och t-VNS®-behandling? Kontakta oss gärna.